tiprankstipranks
Advertisement
Advertisement
BioVie Inc.’s NE3107: A Promising Study for Long COVID Relief
PremiumCompany AnnouncementsBioVie Inc.’s NE3107: A Promising Study for Long COVID Relief
8M ago
BioVie Inc.’s NE3107 Study: A New Hope for Early Parkinson’s Treatment
Premium
Company Announcements
BioVie Inc.’s NE3107 Study: A New Hope for Early Parkinson’s Treatment
8M ago
BioVie price target adjusted to $12 from $6 at Brookline
Premium
The Fly
BioVie price target adjusted to $12 from $6 at Brookline
10M ago
BioVie presents data on Bezisterim at WCAG-2025
PremiumThe FlyBioVie presents data on Bezisterim at WCAG-2025
11M ago
BioVie Expands Board Amid Drug Development Momentum
Premium
Company Announcements
BioVie Expands Board Amid Drug Development Momentum
11M ago
BioVie appoints Amy Chappell, Kameel Farag to board of directors
Premium
The Fly
BioVie appoints Amy Chappell, Kameel Farag to board of directors
11M ago
BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial
PremiumThe FlyBioVie announces poster on patient-centric accessibility of SUNRISE-PD trial
1y ago
BioVie Approves Reverse Stock Split Authority
Premium
Company Announcements
BioVie Approves Reverse Stock Split Authority
1y ago
BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial
Premium
The Fly
BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100